The Smartest Growth Stocks to Invest $10,000 in As Investors Rotate Out of Tech

The article highlights three defensive dividend names with attractive yields: AbbVie at 3.2%, Procter & Gamble at 3.0%, and Enterprise Products Partners at 5.5%. It emphasizes AbbVie’s Dividend King status, P&G’s discounted valuation versus its 5-year averages, and Enterprise’s 27-year annual distribution growth with 1.7x coverage and investment-grade credit. The piece is primarily portfolio-positioning commentary for risk-off investors rotating out of tech, rather than a catalyst-driven event.

Analysis

This is less a “buy dividends” call than a duration trade disguised as income. In a late-cycle or growth-scare tape, capital tends to rotate into cash-flow visibility, but the second-order winner is not just the highest yield — it is the business with the cleanest path to preserving payout growth through a slower macro. EPD stands out because fee-based volumes and contractual cash generation make it the closest thing here to a rate-sensitive bond proxy with operating leverage, while ABBV and PG are more defensive compounding assets than true hedge instruments.

The market is likely underappreciating how much of the relative performance driver is valuation compression normalization, not just yield. PG’s recent multiple reset gives it room to rerate if bond yields stall or fall, while ABBV’s post-Humira narrative can improve as investors become more willing to pay for internal pipeline execution rather than headline patent risk. The risk is that if rates back up another leg, these names can de-rate even if fundamentals remain intact, because their buyer base is crowded with yield-seeking capital that behaves duration-like on the downside.

Contrarian angle: the best risk-adjusted setup may be the one with the least obvious “safety” label. EPD’s distribution looks more durable than the market often assumes, and its yield spread versus Treasuries can remain compelling even if the Fed stays higher for longer; that creates room for multiple expansion on top of income. By contrast, ABBV and PG can both become expensive if the market crowds into defensives too aggressively, making them vulnerable to a reversal once panic subsides.

Key Decisions for Investors

• Go long EPD on a 3-6 month horizon as a high-carry defensive: yield plus modest multiple expansion can deliver mid-teens total return if rates stabilize; use a 10-12% trailing stop given MLP sentiment risk.
• Use PG as a lower-volatility hedge against a growth selloff, but only on pullbacks toward prior valuation support; upside is likely low-double-digit over 6-12 months, so avoid chasing after a defensive bid.
• Prefer ABBV over higher-beta healthcare peers as a quality income long, but size it as a relative-value position rather than an absolute bet; the catalyst window is 1-2 quarters as pipeline confidence offsets residual patent overhang.
• Pair long EPD / short a rate-sensitive high-multiple dividend proxy if available, to isolate yield carry from duration risk; this should outperform if the market remains risk-off but rates do not fall quickly.